Shuhua Zheng, D.O., Ph.D.
Cofounder & CEO
Zheng graduated from the doctoral program in University of Miami, majored in Cancer Biology. His work led to the Phase I clinical trial of a novel compound MLN 4924 in resistant and relapsed acute lymphoblastic leukemia. He is an incoming physician resident of Radiation Oncology in the Northwestern University.
Zheng Ao, Ph.D.
VP & Chief Scientist
Ao received his Ph.D.. from the University of Miami in Cancer Biology, where he pursued his research interests in studying circulating tumor cell and cancer metastasis. After that, he joined Stanford Research Institute as a postdoc fellow to continue developing lung cancer early diagnosis liquid biopsy tests. Now he is continuing his research at Indiana University to develop cancer immunotherapy such as CAR-T.
Yilin Wu, Ph.D.
Cofounder & COO
Wu received her Ph.D. in Mathematics from Temple University in Philadelphia. Now she is severing as an Assistant Professor at DigiPen Institute of Technology in both Singapore and US campuses. Her research interests and skills include mathematical modeling, data analysis, machine learning, and deep learning.
Ke Jin, Ph.D.
Chief Research Director
Jin got his Ph.D. degree at University of Miami, majoring in Cancer Biology. He focused on elucidating the molecular mechanism of signaling pathways in cancer through both biochemical and biological study. He is currently a postdoctoral on immunology at Stanford University. Jin takes direct charge of laboratory developments in Kancure.